<DOC>
	<DOCNO>NCT02088203</DOCNO>
	<brief_summary>Safety tolerability soy-protein Russian Tarragon complex versus placebo .</brief_summary>
	<brief_title>Evaluation Soy-protein Russian Tarragon ( Artemisia Dracunculus L . )</brief_title>
	<detailed_description>Plants genus Artemisia , specifically Artemisia dracunculus L. ( Russian tarragon ) long history medicinal ( health ) culinary ( food ) use report effective traditional treatment diabetes various part world . The overall objective study conduct early human investigation evaluate effect nutritional supplementation well characterize extract Artemisia dracunculus L. The primary objective would evaluate safety , tolerability effective dose non-diabetic human subject . Secondary objective would assess metabolism extract evaluate effect propose mechanism insulin secretion , lipid level and/or insulin resistance . After complete screen visit meeting qualification single oral dose evaluation , subject receive three single dos ( two different dos supplement one dose placebo ) three separate test period separate washout period least 7 day . Each test period require overnight stay inpatient unit . The inpatient stay approximately 26 hour . The dos use study 0.3 , 1 , 3 , 10 , 20 30 gram plus placebo . The supplement placebo mixed sugar-free flavoring water . There opportunity sample liquid drink screen visit . Screening visit 1 ( 1 hour ) - Fasting ( Nothing eat drink water least 10 hour prior appointment ) - Sign informed consent willing participate - Body weight height measure ( body mass index calculate measure ) - Blood pressure , pulse temperature measure - Physical exam ECG ( electrocardiogram ) - Report medication take past 3 month - Blood draw ( 2 teaspoon ) assess overall health - Taste test ALL PROCEDURES AND VISITS LISTED BELOW WILL BE REPEATED 3 TIMES . ALL TESTING WILL BE DONE FOR EACH SINGLE DOSE TESTING PERIOD ( 1,2,3 ) - Testing Period 1 : Day -3 , Day 1 , Day 2 - 7 Day Washout - Testing Period 2 : Day -3 , Day 1 , Day 2 - 7 Day Washout - Testing Period 3 : Day -3 , Day 1 , Day 2 Day -3 ( 4 hour ) Fasting ( Nothing eat drink water least 10 hour prior appointment ) - Blood pressure , pulse temperature measure - An IV line place arm vein blood draw purpose remain throughout test . - A blood draw ( approximately 2 teaspoon ) do dose ass change glucose insulin . - An Oral Glucose Tolerance Test ( OGTT ) do A blood sample drawn IV line , subject drink sugar solution consist 75 gram glucose . Blood drawn specific time drink consume . Each blood sample 1 tablespoon . ( 6 tablespoon total test ) . During IV procedure , small amount subject 's blood ( le 1 teaspoon ) immediately return vein IV specimen collect . - Adverse event change medication assessed staff - Meet staff briefly dietary intake weight maintenance diet Day 1 ( Inpatient Stay- 26 hour ) Fasting ( Nothing eat drink water least 10 hour prior appointment ) - Admission inpatient unit morning Day 1 visit . The subject remain unit overnight discharge Day 2 . - Blood pressure , pulse temperature measure . - Randomization study dose scheme occur . Randomization like flip coin . You study staff know dose receive receive placebo ( inactive pill ) . - Single dose extract give ( either supplement placebo ) . The dose give 2 hour prior start OGTT . The extract powder form mix 8 ounce liquid drink . - An IV line place arm vein blood draw purpose remain throughout test . - OGTT describe ( day -3 ) . - A blood draw ( approximately 2 teaspoon ) dose do ass change glucose insulin . Blood draw occur 30 , 60 , 90 , 120 , 180 , 240 minute 12 hour dose . - An ECG perform perform . - Adverse event change medication assessed staff . - The subject ask fast overnight blood work Day 2 . Day 2 ( Inpatient ) Blood pressure , weight , pulse temperature measure . - A physical exam do - A 24 hour post dose blood draw ( approximately 1 teaspoon ) do . - Study staff schedule next test period applicable subject discharge inpatient unit .</detailed_description>
	<criteria>Are overall healthy adult Are male female , age 1865 time consent Are female childbearing potential , must agree use one approve contraception method [ ( i.e. , barrier method , intrauterine cervical device , oral contraceptive , hormonal injection ( Depo ProveraÂ® ) , condom spermicidal gel foam , contraceptive patch ( Ortho Evra ) , diaphragm , abstinence ) ] , prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit . Have BMI within range 18.532 kg/m2 ( measure height weight ratio ) . Are capable give write informed consent , include compliance requirement restriction list consent form . Have significant cardiac , pulmonary , gastrointestinal , hepatic , renal , hematological , endocrine , neurological psychiatric disease Have overall normal clinical laboratory test deem physician Have prior history Type 1 2 diabetes Are female pregnant lactating . Are take certain medication ( review study staff ) . Are anticipate plan surgery study period . Are current smoker smoke within previous 6 month . Have weight change 5 % last 2 month . Are take prescription counter medication supplement weight loss .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>